Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for rare liver diseases. The company was founded in 2018 and is headquartered in Foster City, California, United States. Mirum's mission is to provide innovative treatment options for patients with rare, chronic liver diseases where there is a significant unmet medical need. Mirum Pharmaceuticals is listed on the NASDAQ stock exchange under the ticker symbol "MIRM."
The company's flagship product is maralixibat, an investigational drug designed to treat cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis. Cholestatic pruritus is a severe itching condition that affects individuals with liver disorders. Maralixibat works by reducing bile acid buildup, which is believed to be the underlying cause of pruritus. The drug has shown promising results in clinical trials and has the potential to become a breakthrough treatment for these rare liver diseases.
Mirum Pharmaceuticals is dedicated to developing and commercializing innovative therapies that address the unmet medical needs of patients with rare liver diseases. The company collaborates with healthcare professionals, patient advocacy groups, and regulatory authorities to advance its research and bring novel treatments to the market.
Mirum Pharmaceuticals has a pipeline of other investigational drugs targeting different rare liver diseases. The company's research and development efforts focus on identifying and developing therapies that can make a significant difference in the lives of patients with these conditions.
Mirum's commitment to rare liver diseases and its focus on developing targeted treatments make it a notable player in the biopharmaceutical industry. With its innovative approach and dedicated team, Mirum Pharmaceuticals aims to improve the quality of life for patients affected by rare liver diseases and contribute to the advancement of medical science in this field.